Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Disease

PHASE3TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

September 2, 2020

Primary Completion Date

July 29, 2022

Study Completion Date

July 29, 2022

Conditions
Polycystic Kidney Disease, AdultADPKD
Interventions
DRUG

Lixivaptan

Oral vasopressin V2 receptor antagonist

Trial Locations (6)

18107

Northeast Clinical Research Center, LLC, Bethlehem

22033

Nephrology Associates of Northern Virginia, Inc., Fairfax

27103

Brookview Hills Research Associates, LLC, Winston-Salem

55905

Mayo Clinic, Rochester

60637

University of Chicago Medicine & Biological Sciences, Chicago

90025

University of California Los Angeles, Los Angeles

Sponsors
All Listed Sponsors
collaborator

Centessa Pharmaceuticals plc

INDUSTRY

lead

Palladio Biosciences

INDUSTRY

NCT04152837 - Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Disease | Biotech Hunter | Biotech Hunter